mobocertinib,Amivantamab,trastuzumab deruxtecan
Takeda,Janssen,daiichi sankyo,astrazeneca
['nsclc', 'sclc']
very interesting review of current scenario of egfr ins20 and her-2 mutant nsclc #esmo22 
Medicine at @USAL | Medical Oncology, Hospital Universitario 12 de Octubre #thoracictumours #lungcancer  | PhD student @unicomplutense | ??